α₁-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease.

ABSTRACT: Corticosteroid resistance after acute graft-versus-host disease (SR-aGVHD) results in high morbidity and mortality after allogeneic hematopoietic cell transplantation. Current immunosuppressive therapies for SR-aGVHD provide marginal effectiveness because of poor response or excessive toxicity, primarily from infection. α₁-Antitrypsin (AAT), a naturally abundant serine protease inhibitor, is capable of suppressing experimental GVHD by downmodulating inflammation and increasing ratios of regulatory (T_reg) to effector T cells (T_effs). In this prospective multicenter clinical study, we sought to determine the safety and response rate of AAT administration in SR-aGVHD. Forty patients with a median age of 59 years received intravenous AAT twice weekly for 4 week

SUBMITTER: Magenau JM 

PROVIDER: S-EPMC5865235 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature